
 
													
 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recombinant Human Growth Hormone is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Achondroplasia.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
April 29, 2022
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Children's Hospital of Fudan University | Tongji Medical College, Huazhong University of Science and Technology | Beijing Children's Hospital | Peking University First Hospital | Peking Union Medical College Hospital | The Children's Hospital of Zhejiang
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recombinant Human Growth Hormone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prader-Willi Syndrome.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 12, 2018
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Children's Hospital of Fudan University | Tongji Medical College, Huazhong University of Science and Technology | Beijing Children's Hospital | Peking University First Hospital | Peking Union Medical College Hospital | The Children's Hospital of Zhejiang
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Children's Hospital of Fudan University | Beijing Children's Hospital | Shanghai Children's Hospital | Xin Hua Hospital, Shanghai Jiaotong University School of Medicine | The Children's Hospital of Zhejiang University School of Medicine | Children's Hospi
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recombinant Human Growth Hormone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dwarfism.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
May 24, 2018
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Children's Hospital of Fudan University | Beijing Children's Hospital | Shanghai Children's Hospital | Xin Hua Hospital, Shanghai Jiaotong University School of Medicine | The Children's Hospital of Zhejiang University School of Medicine | Children's Hospi
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recombinant Human Growth Hormone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
August 10, 2017
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Recombinant Human Growth Hormone on HIV Persistence
Details : Somatotropin is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
March 27, 2017
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Peking University Third Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recombinant Human Growth Hormone is a Hormone drug candidate, which is currently being evaluated in clinical studies for the treatment of Polycystic Ovary Syndrome.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 16, 2016
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Peking University Third Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)
Details : Genotropin is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 22, 2013
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)
Details : Recombinant Human Growth Hormone is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dwarfism, Pituitary.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
May 24, 2012
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Rebecca Knickmeyer Santelli, PhD
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome
Details : Somatotropin is a Hormone drug candidate, which is currently being evaluated in clinical studies for the treatment of Turner Syndrome.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 07, 2011
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Rebecca Knickmeyer Santelli, PhD
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)
Details : Somatotropin is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Infertility.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
September 17, 2010
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All